The IMF is very pleased to have established a partnership with AbbVie to conduct the largest, most comprehensive chart-review study of myeloma patients with the t(11;14) translocation evident on FISH (fluorescence in situ hybridization) testing of bone marrow myeloma cells. This landmark retrospective analysis assesses the 16-to-24-percent of myeloma patients harboring the t(11;14) translocation. The...Continue Reading

Multiple Myeloma action month March 2018: Thanks to medical innovation, Multiple Myeloma patients are living longer than ever before. Multiple Myeloma (MM) is the second most commonly diagnosed blood cancer after non-Hodgkin lymphoma, yet few people know much about this deadly disease. The American Cancer Society’s estimates for multiple myeloma in the United States for...Continue Reading